Teva and Prestige Biopharma enter license agreement for Tuznue (trastuzumab biosimilar) commercialization in Europe

Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets. Tuznue is approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received the European Commission (EC) marketing authorization for Tuznue in September 2024. Under the terms of the license and supply agreement, Teva secured rights to market and distribute Tuznue in a majority of European markets, leveraging its extensive commercial network and proven expertise in biosimilars. Prestige Biopharma will be responsible for production and supply through its EU-GMP-certified, high-tech facilities equipped with advanced single-use technology.

“We are passionate about the future of biosimilars and the value they bring to patients and healthcare systems,” said Richard Daniell, Executive Vice President, European Commercial, Teva. “Our deep commercial experience in biosimilars and broad sales and marketing reach across Europe enables us to bring critical medicines to patients. We are looking forward to working together with Prestige to make Tuznue a commercial success in Europe.”

“We are excited to collaborate with Teva, a global biopharmaceutical leader, to bring Tuznue to patients across Europe,” said Lisa Park, CEO of Prestige Biopharma. “This collaboration is a significant step in establishing Prestige Biopharma as a global biopharmaceutical leader. Teva’s extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline, including bevacizumab and 14 additional candidates.” The approval marks a major milestone for Prestige’s biosimilar portfolio, signaling progress in expanding access to cost-effective treatments across Europe.